David M. Albala, MD, Andrew Hahn, MD, Brian T. Helfand, MD, PhD, Ronald P. Kaufman, Jr., MD, Christian P. Pavlovich, MD, and A. Oliver Sartor, MD, presented “Panel Discussion: Molecular Targeted Imaging (MTI)” during the 35th International Prostate Cancer Update conference on February 9, 2025, in Vail, Colorado.
This content is available free to the GRU Community. Login or create an account to view it.
How to cite: Albala, David M.; Hahn, Andrew; Helfand, Brian T.; Kaufman, Jr., Ronald P.; Pavlovich, Christian P.; Sartor, A. Oliver. “Panel Discussion: Molecular Targeted Imaging (MTI).” February 9, 2025. Accessed Jan 2026. https://grandroundsinurology.com/panel-discussion-molecular-targeted-imaging-mti/
Panel Discussion: Molecular Targeted Imaging (MTI) – Summary#
In this 21-minute discussion, the panel addresses intermittent versus continuous androgen deprivation therapy (ADT) and its impact on prostate cancer outcomes.
The panelists highlight the importance of precision oncology, focusing on tumor biology and patient-specific risks to guide treatment choices. They advocate for a chronic disease model approach in managing biochemical recurrence. The discussion also covers the PSMA DC trial comparing lutetium therapy versus no systemic therapy in metastatic cases with negative conventional imaging. The conversation highlights emerging PET imaging technologies, including copper-based PET scans, which promise improved sensitivity and accuracy. The talk concludes by discussing improving patient outcomes through personalized strategies, combining early intervention with precise imaging and risk assessment.
About the 35th International Prostate Cancer Update:
The International Prostate Cancer Update (IPCU), is a multi-day, CME-accredited conference focused on new developments in prostate cancer treatment, diagnosis, and prevention. IPCU 35 will feature lectures, interactive discussions, panel roundtables, debates, and case reports. This conference is led by expert physicians and is designed for urologists, medical oncologists, radiation oncologists, and other healthcare professionals involved in the diagnosis and treatment of prostate cancer.
The goal of this educational program is to equip healthcare professionals involved in the diagnosis and treatment of prostate cancer with the up-to-date clinical knowledge and tools they need to best treat their patients. The program will discuss the treatment of prostate cancer from diagnosis to treating advanced and metastatic disease. The conference aims to give physicians exposure to a comprehensive review of treating prostate cancer patients and to give them a chance to discuss the issues with peers and experts. You can learn more about the conference here.
ABOUT THE AUTHOR
Dr. Christian P. Pavlovich is a renowned urologist specializing in urologic oncology, focusing on prostate and kidney cancers. He is the Bernard L. Schwartz Distinguished Professor in Urologic Oncology at Johns Hopkins University School of Medicine and directs the Prostate Cancer Active Surveillance Program. Dr. Pavlovich is known for his expertise in minimally invasive and robotic surgeries, as well as his pioneering work in cancer detection and active surveillance strategies. He is dedicated to providing personalized, high-quality care to patients with urologic cancers.
